Vascular Biogenics Ltd (VBLT)

[davidal66]

This is why, I'm expecting and hoping for a two-three month final separation of the KM curves and have been for some time. Also, when you look at the data for rGBM, with Avastin, there is no change or improvements in the past 8 years that I can see.

If you plug in the all the numbers for patients who were eligible for the high-dose multiple dosage cohort of the phase II rGBM trial and achieve a 11.5-12 month overall survival average as noted in the prior post, then come up with a 7.5-9.5 overall survival average for Avastin, you come up with a meaningful improvement in survivorship. Not a doubling of survival but a 20-30 % improvement. Throw into the mix a small percentage of CR's and more PR's than the Avastin only arm, and you have a meaningful improvement in therapy in a market desperate for new therapies.